FDA - CDER/OPQ/Office of Regulatory Practice for Pharmaceutical Quality (ORPPQ)
Policy Lead
Eric Dong currently serves as a Policy Lead in the Office of Pharmaceutical Quality (OPQ) within the Center for Drug Evaluation and Research (CDER) at the U.S. FDA. In this role, he is responsible for developing science- and risk-based policies and standards related to drug product quality. Since 2022, he has led policy development efforts for advanced manufacturing technologies and CDER's Framework for Advanced Manufacturing Evaluation (FRAME) initiative, with a focus on distributed manufacturing (DM) and artificial intelligence (AI) in pharmaceutical manufacturing. Prior to his current policy role, Eric served as a Consumer Safety Officer responsible for assessing post-approval drug quality in the Office of Quality Surveillance (OQS) within OPQ/CDER. Before joining CDER, Eric spent five years in FDA's Office of Inspections and Investigations (OII), where he served as a chemist and drug investigator conducting domestic and international CGMP inspections. Eric received his B.S. in Chemistry from the State University of New York (SUNY) at Binghamton University and his M.S. from Temple University.